KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Capital Expenditures: 2009-2025

Historic Capital Expenditures for Thermo Fisher Scientific (TMO) over the last 16 years, with Sep 2025 value amounting to $404.0 million.

  • Thermo Fisher Scientific's Capital Expenditures rose 48.53% to $404.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year increase of 16.23%. This contributed to the annual value of $1.4 billion for FY2024, which is 5.34% down from last year.
  • According to the latest figures from Q3 2025, Thermo Fisher Scientific's Capital Expenditures is $404.0 million, which was up 37.41% from $294.0 million recorded in Q2 2025.
  • Over the past 5 years, Thermo Fisher Scientific's Capital Expenditures peaked at $831.0 million during Q4 2021, and registered a low of $272.0 million during Q3 2024.
  • Its 3-year average for Capital Expenditures is $358.1 million, with a median of $347.0 million in 2024.
  • As far as peak fluctuations go, Thermo Fisher Scientific's Capital Expenditures spiked by 148.22% in 2021, and later tumbled by 43.87% in 2023.
  • Over the past 5 years, Thermo Fisher Scientific's Capital Expenditures (Quarterly) stood at $831.0 million in 2021, then tumbled by 33.81% to $550.0 million in 2022, then declined by 26.36% to $405.0 million in 2023, then climbed by 18.52% to $480.0 million in 2024, then skyrocketed by 48.53% to $404.0 million in 2025.
  • Its Capital Expenditures was $404.0 million in Q3 2025, compared to $294.0 million in Q2 2025 and $362.0 million in Q1 2025.